Abstract | BACKGROUND: In patients with bone pain due to metastatic disease, intravenous systemic radioisotope therapy may be a useful adjunct to other methods for palliating pain. METHODS: Various studies have been performed utilizing a short-lived radioisotope conjugated to a tetraphosphonate ( samarium 153 lexidronam) both as an open label and as a double blinded, placebo-controlled study. Patients with varying tumor types including those of the prostate, breast, lung, and other sites were studied. Two dose levels were used (0.5 millicuries (mCi)/kg and 1.0 mCi/kg) with patients monitored for 16 weeks for efficacy ( pain scores, opiod analgesic score, and quality of life) parameters and adverse events. RESULTS: All 3 studies showed that at the 1.0 mCi/kg dose level statistically significant improvement over placebo was observed by 4 weeks with relief of pain noted in many patients by 1 week. The only significant adverse event was transient myelosuppression with a nadir at 4-6 weeks and recovery by 8 weeks. Less than 10% of patients had National Cancer Institute Common Toxicity Criteria Grade III/IV bone marrow toxicity recorded. CONCLUSIONS: Systemic metabolic radiotherapy with samarium 153 lexidronam appears to be a safe and efficacious method for treating patients with bone pain. The shorter radioisotope half-life allows for a high dose rate to be delivered over a short period, which may have certain biologic benefits.
|
Authors | A N Serafini |
Journal | Cancer
(Cancer)
Vol. 88
Issue 12 Suppl
Pg. 2934-9
(Jun 15 2000)
ISSN: 0008-543X [Print] United States |
PMID | 10898337
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Review)
|
Chemical References |
|
Topics |
- Bone Neoplasms
(physiopathology, radiotherapy, secondary)
- Clinical Trials as Topic
- Humans
- Pain Management
- Palliative Care
- Samarium
(adverse effects, pharmacokinetics, therapeutic use)
|